Short Interest in VolitionRx Limited (NYSEAMERICAN:VNRX) Rises By 23.6%

VolitionRx Limited (NYSEAMERICAN:VNRX) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 546,400 shares, an increase of 23.6% from the October 31st total of 441,900 shares. Based on an average daily trading volume, of 123,400 shares, the short-interest ratio is currently 4.4 days.

VolitionRx Price Performance

VNRX traded down $0.06 during trading on Monday, hitting $0.64. 333,382 shares of the stock traded hands, compared to its average volume of 163,192. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The company has a market cap of $40.23 million, a P/E ratio of -1.23 and a beta of 1.59.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.